Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

432.81 -12.62 (-2.83%)
Streaming Delayed Price Updated: 11:38 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
2 Safe-and-Steady Stocks with Impressive Fundamentals and 1 We Avoid
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
United Therapeutics Corp (NASDAQ:UTHR) Offers Affordable Growth with Strong Profitability
United Therapeutics offers strong growth, high profitability, and a robust balance sheet, yet trades at a significant discount to the biotech industry. A top pick for affordable growth. 
Via Chartmill
United Therapeutics (UTHR) Earnings Transcript
United Therapeutics (UTHR) Earnings Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls. 
Via Investor's Business Daily
Earnings Scheduled For October 29, 2025
 
Via Benzinga
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
Via Stocktwits
UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per... 
Via StockStory
Why Is United Therapeutics (UTHR) Stock Soaring Today
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 11.7% in the afternoon session after the company reported record third-quarter financial results and announced positive outcomes... 
Via StockStory
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday?
A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100... 
Via Benzinga
Topics Economy Stocks
United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short
Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso. 
Via Investor's Business Daily
United Therapeutics Corp (NASDAQ:UTHR) Reports Q3 2025 Earnings: Revenue Misses, EPS Beats Estimates
United Therapeutics posts record Q3 2025 revenue of $799.5M, driven by strong Tyvaso growth. The company beat EPS estimates but slightly missed on revenue. 
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per... 
Via StockStory
A Peek at United Therapeutics's Future Earnings
 
Via Benzinga
United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings this Wednesday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
If You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much Today
 
Via Benzinga
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market... 
Via MarketMinute
Topics Retirement
United Therapeutics Corp (NASDAQ:UTHR) Meets Key Peter Lynch Investment Criteria
United Therapeutics (UTHR) aligns with Peter Lynch's investment strategy, showing strong earnings growth, a fair PEG ratio, and a debt-free balance sheet for long-term value. 
Via Chartmill
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Prime Value Investment Candidate
United Therapeutics (UTHR) is a strong value stock with a low P/E ratio, zero debt, high profitability, and solid growth, making it an undervalued biotech pick. 
Via Chartmill
1 Value Stock for Long-Term Investors and 2 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
2 Growth Stocks with All-Star Potential and 1 Facing Headwinds
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
1 Momentum Stock to Target This Week and 2 We Brush Off
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
3 Big Reasons to Love United Therapeutics (UTHR)
United Therapeutics currently trades at $412.41 and has been a dream stock for shareholders. It’s returned 308% since September 2020, tripling the S&P 500’s 103% gain. The company has also beaten the... 
Via StockStory
Topics Stocks
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Top Peter Lynch-Style GARP Investment
United Therapeutics (UTHR) aligns with Peter Lynch's GARP strategy, featuring strong EPS growth, a PEG below 1, zero debt, and robust financial health. 
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga
United Therapeutics Corp (NASDAQ:UTHR): A Prime Value Investing Candidate with Strong Fundamentals
United Therapeutics (UTHR) is a strong value investing candidate with low P/E, zero debt, high profitability, and excellent financial health, offering a solid margin of safety. 
Via Chartmill
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.